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Although  human Ia antigens were first recognized on B  lymphocytes and macro- 
phages  (1,  2),  recent  studies  have  revealed  that  Ia antigens  are  also  expressed on 
normal T  cells (3-5), Langerhans cells (6), and some malignant cells (7, 8). A central 
role for Ia antigens  in  the regulation  of immune responsiveness is suggested by the 
observations that antibodies to Ia inhibit antigen presentation (9) and bind soluble T 
cell-derived i mmunoregulatory factors (10-13). Ia-positive cells have been reported to 
be necessary in  autologous and  allogeneic mixed lymphocyte reactions  (auto-MLR 
and allo-MLR) 1 (14)  and to play a  significant role in suppressor cell functions  (15, 
16). 
In some presumed autoimmune diseases, such as rheumatoid arthritis and systemic 
lupus erythematosus (SLE)  (17)  as well as in infectious mononucleosis (18)  and graft- 
vs.-host  reaction  (19),  an  increase  in  peripheral  blood  Ia-positive T  cells  has been 
recorded.  Yu  et  al.  (17)  have reported  that  the percentage of peripheral  blood Ia- 
positive T  cells in normals increases after tetanus immunization or skin testing with 
purified protein derivative (PPD).  In the present report, we also found an elevation 
of Ia-positive T  cells in three of six immunizations in vivo, whereas, in the remaining 
three individuals studied, a  slight decrease was observed. A  more consistent finding, 
however, was the production of IgM anti-Ia-reactive antibodies after in vivo immu- 
nization or antigenic stimulation. These naturally occurring anti-Ia antibodies might 
regulate the percentage of Ia-positive T  cells in peripheral blood. 
Materials and Methods 
Preparation of Lymphocytes.  Peripheral blood mononuclear cells (PBMC) were separated from 
heparinized blood of normal donors by differential centrifugation over Ficoll-Hypaque. Purified 
T cells were obtained by incubation of PBMC with neurarninidase-treated sheep erythrocytes 
(SRBC)  at 4°C for 1 h with subsequent Ficoll-Hypaque gradient centrifugation. The SRBC 
obtained  in  the  rosetting  fraction  were  lysed  with  ammonium  chloride-Tris buffer.  After 
washing, adherent cells were removed by incubation at 37°C for 45 min on glass petri dishes. 
Such T cell preparations were assayed for purity (>97%) using immunofluorescence and mouse 
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hybridoma antibody 9.6 reacting with E-rosette receptors (20). In addition, T cell preparations 
showed < 1% cells with surface immunoglobulins  (Ig) and <2% peroxidase-positive cells. 
Monodonal Antibodies.  Mouse hybridoma anti-Ia monoclonal antibody (clone L243;  B-D 
Immunodiagnostics, Becton, Dickinson & Co. Orangeburg, NY) was used. This reagent reacts 
with the common or core determinant of human Ia antigen and precipitates 28,000 and 34,000 
mol wt chains from 125I-labeled NP-40 extracts of human B cell lines (21). 
Monoclonal Antibody  Rosetting  Technique for  Determination of Ia-positive  T  Cells.  The  precise 
methods of the rosetting technique have been previously described (22). Briefly,  T  cells were 
incubated with  anti-Ia monoclonal antibody for  30  rain at  4°C,  then  washed  twice  with 
phosphate-buffered saline (PBS) and mixed with affinity-purified goat anti-mouse IgG (Tago 
Inc., Burlingame, CA) coupled by chronic chloride treatment to ox erythrocytes. The mixture 
was centrifuged for 10 rain at 200 g, incubated for 30 min on ice, and the percentage ofrosetting 
cells counted. 
Measurement of Density of Ia  Anttgen on  Cells Using the Fluorescence-activated Cell Sorter (FACS). 
E-rosette-negative cells were analyzed for Ia antigen by reacting with fluorescein-conjugated 
monoclonal anti-Ia antibody (Becton,  Dickinson &  Co.)  with  subsequent measurement of 
fluorescence intensity on an FACS-III (B-D FACS systems;  Becton, Dickinson & Co.).  A cell 
pellet  containing l0  s cells  was  incubated for  30  min on  ice  with  50  /11  of fluoresceinated 
monoclonal anti-Ia (20 mg/ml). The cells were washed twice in a refrigerated centrifuge with 
PBS containing  0.01% azide and then were suspended in 1% paraformaldehyde-PBS and stored 
at 4°C. Cells obtained before and at days 1 through 7 after skin testing were all analyzed on 
the same day. 
Blocking of Anti-Ia Monoclonat Antibody-binding by Serum Samples.  The precise methods have also 
been described in our previous report (22). Briefly, T cells were preincubated with 100/~1 of test 
serum samples for  1 h  at 4°C, followed  by incubation with appropriate dilutions of anti-Ia 
monoclonal antibody in the presence of serum samples. After sensitization, cells were washed, 
and the percentage of positive cells was analyzed using the rosette technique. The capacity of 
serum samples to block the binding of anti-Ia monoclonal antibody was assessed and reported 
as percent inhibition. In our previous report  (22) on anti-Ia blocking activity in the sera of 
patients with SLE, we demonstrated that the rosette assay described above correlated well with 
the results of a similar analysis using an FACS. We also showed that the blocking activity was 
not  reduced  by pepsin digestion or  ultracentrifugation, ruling out  the  possibility that  the 
blocking activity was the result of immune complexes. 
Anti-Ia-reactive Antibody Detected by ELISA Assay.  An Ia-positive B cell line, B35 M, was used 
as a target cell substrate. 50 #1 of poly-L-lysine (PLL) (Sigma Chemical Co., St. Louis, MO) (50 
/~g/ml  in PBS)  was placed in flat-bottomed flexible mierotit~r plates (Dynatech Laboratories 
Inc., Dynatech Corp., Alexandria, VA). Plates were incubated for 1 h at 37°C. After incubation, 
the wells were washed twice with PBS, and B35 M cells (5 ×  104 cells/well) were added to each 
well with adherence to the bottom of the wells after centrifugation at  1,500 rpm for  10 min. 
After centrifugation, wells were washed once with PBS, and the remaining binding sites in the 
wells were blocked with  100/~1 of 50%  fetal calf serum  (FCS)  and incubated 2 h  at  room 
temperature. 
After incubation, the wells were washed three times with PBS; 25/~1 of serum samples was 
added to the wells  in triplicate and incubated 1 h  at  room temperature, and then 25 ~1 of 
monoclonal anti-Ia antibody (4 #g/ml in PBS +  10%  FCS)  was  added to the wells without 
washing (final concentration of monoclonal anti-Ia antibody was  2 p.g/ml). The microtiter 
plates were then incubated for 30 rain at room temperature, and wells were washed three times 
with PBS. After washing, 50 #1 of peroxidase-conjugated, affinity-purified goat anti-mouse IgG 
(Tago Inc.) was added (1:1000  dilution in PBS with  10% FCS) and incubated at 4°C for 30 
min. After washing, 100 ~1 of the substrate, 0.02% 2.2-azino-di-3-athylbenzthiazolin-sulfonate) 
in 2.3% citric acid buffer (pH, 4.0) with 0.17% hydrogen peroxide was added to the wells. After 
30 min incubation at room temperature, the reaction was stopped by adding citric acid buffer, 
pH 2.8. The light absorbance of wells was measured by an automated ELISA reader (Dynatech 
Laboratories, Inc., Dynatech Corp.) To construct a standard curve, different final concentra- 
tions of monoclonal anti-Ia antibody were added to the wells in the presence of normal human 
serum (NHS) or FCS (Fig.  1). In preliminary experiments, different numbers of B35 M  cells K.  OKUDAIRA, J.  S.  GOODWIN,  AND  R.  C.  WILLIAMS, JR. 
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Fta.  1.  Standard curve of binding of monoclonal anti-la antibody to microtiter wells coated with 
B35 M  cells. 50,000 B35 M  cells, an la-positive cell line, were adhered to microtiter plates with 
poly-L-lysine. Different  qualities of anti-la antibody were incubated in the wells, then washed,  and 
affinity-purified, peroxidase-coupled goat anti-mouse IgG was added. After washing,  substrate  was 
added, and the optical density at 410 nM was measured.  In other experiments, like that in Fig. 4, 
a concentration of 2 #g/ml of the monoclonal anti-la antibody was used, and the ability of various 
sera samples to block the binding was measured. 
were  adhered  to  the  plates.  There  was  a  linear  increase  in  binding  of monoclonal  anti-Ia 
antibody with increasing numbers of B35 M  cells up to 5 ×  l04 cells/well, above which there 
was little additional increase in binding of anti-Ia. 
Detection of Anti-Ia  Antibodies by ELISA  Using Purified Ia Antigen.  Ia  antigens  were purified 
from B35 M  cells by a  method modified from that  of Winchester et al.  (23).  Briefly, 15 ml of 
packed  B35  M  cells were lysed with  freeze-thawing and  hypotonic washing.  The membrane 
preparation was solubilized with 5% sodium deoxycholate, and the preparation was centrifuged 
at  100,000 g  for  1 h. The supernatant  was passed  over an ultragel A  34 column equilibrated 
with 0.01  M  Tris-HCl (pH, 8.0), 0.15  M  NaC1, 0.001  M  EDTA, and 0.1% deoxycholate. The 
eluted aliquots were assayed by enzyme-linked immunosorbent assay (ELISA) technique using 
rabbit IgG anti-Ia antibody coated to plates, followed by the antigen fractions and subsequent 
addition of mouse monoclonal anti-Ia conjugated with peroxidase. Fractions with high activity 
were pooled and subjected to  10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 
2-mm  slices of the  gels were eluted  with  PBS  plus  30%  FCS and  tested  for activity by  the 
ELISA assay. Gel isolation and assay confirmed that human Ia antigenic materials represented 
28,000- and 34,000-mol wt bands. 
100/d of Ia antigen (3/*g/ml in PBS) was placed in flat-bottomed flexible microtiter plates 
(Dynatech  Laboratories  Inc., Dynatech Corp.)  Plates were incubated  overnight at 4°C. After 
incubation, the wells were washed with PBS, and the remaining binding sites in the wells were 258  ANTI-IA ANTIBODY  IN THE  SERA  OF NORMAL SUBJECTS 
blocked by incubating with  100 #l of 2%  bovine serum albumin-PBS  (BSA-PBS)  for 2 h  at 
room temperature. 
After incubation, the wells were washed three times with PBS, and  100/~1 of diluted serum 
samples (20% in PBS-BSA) was added to the wells in duplicate and incubated  1 h  at room 
temperature. After incubation, the wells were washed once with PBS-Tween 80 (0.05% Tween 
80, 0.01% sodium azide) and twice with PBS, and then 100 #1 of pe~oxidase-conjugated affinity- 
purified goat anti-human IgG and IgM (Tago Inc.) was added (1:500 dilution in PBS-BSA) 
and incubated 30 rain at room temperature. The rest of the ELISA was carried out as described 
above. As a background, wells were established without Ia antigen. 
To quantitate the amount of IgG and IgM bound to the wells, different amounts of IgG and 
IgM  (1-200  ng)  were added  to  the  wells and  incubated  overnight  at  4°C.  In  preliminary 
experiments, we examined the percentage of nonspecific binding of IgG and IgM to the wells 
using  125I-labeled  Ig and  found  that  55%  to  65%  of Ig adhere  to  the  wells by  overnight 
incubation at  4°C.  We added peroxidase-conjugated goat anti-human  IgG or IgM  for the 
ELISA assay as described above. We then plotted a  standard curve of IgG or IgM vs. light 
absorption to quantitate the amount of IgG and IgM bound to the wells coated with Ia. 
Absorption of Serum Samples with Cell Lines.  In some experiments, sera samples were absorbed 
with human  cell lines known  to express surface Ia antigen  (B35  M,  Moh-3, W1-L2, RPMI 
4098)  or to be Ia negative (Moh-4) (1, 24).  l-ml serum samples were incubated with 108 cells 
at 4°C for 2 h, and then the cells were removed by centrifugation. 
Affinity  Purification of IgG and IgM from  Serum Samples.  Rabbit anti-human  IgG and  anti- 
human  IgM  (Calbiochem, LaJolla, CA) were conjugated with Sepharose 4B by the method 
described by Porath et al. (25). Serum samples were passed over the column and absorbed IgG 
or  IgM  eluted  using  pH  3.0,  0.1  M  glycine saline  buffer  followed  by  concentration  by 
evaporation and dialysis against PBS. 
Antigenic Stimulation of Normal Subjects with Purified Protein Derivative (PPD), Tetanus Toxoid, and 
Candida Antigen.  Three normal individuals known to show positive delayed-type hypersensitiv- 
ity to PPD were injected intradermally with 0. I ml of PPD (Parke Davis and Co., Detroit, MI); 
two  other  individuals  were  injected  intracutaneously  with  0.02  ml  of Candida  antigens 
(Bioproducts Corp., Tempe, AZ), and one other subject was injected with 0.5 ml of  subcutaneous 
tetanus  toxoid  (Upjohn  Co.,  Kalamazoo,  MI).  Blood  samples  were  collected  before  the 
immunization and at periodic intervals afterwards, and percentage of Ia-positive T cells as well 
as anti-Ia blocking activity of the serum samples was examined using the rosette inhibition 
technique or ELISA assays. As a control, two individuals known to be PPD negative received 
intradermal PPD, and serum samples were collected and analyzed as described above. 
Results 
Fig. 2 shows the inhibition of monoclonal anti-Ia binding to Ia-positive T  cells by 
sera from six subjects before and on days 1 through 7 after skin testing or vaccination. 
In all eases, there was substantial inhibition of the binding of anti-Ia antibody by sera 
obtained  after  in  vivo  antigenic  challenge.  The  inhibitory  activity  was  normally 
present 48 h  after challenge and showed a  peak between 48 and  120 h. In all cases it 
was  gone by day  7.  These same sera caused  no  inhibition of the binding of several 
other monoclonal antibodies directed against T  cells (OKT3) or T  cell subsets (OKT4 
and OKTS; data not shown). As a control, two individuals known to be PPD negative 
were  also  given  PPD.  Sera  from  these  individuals  had  no  effect  on  binding  of 
monoclonal anti-Ia antibody to Ia-positive cells. 
Also graphed in Fig. 2  are serial studies of the percentage of Ia-positive T  cells in 
the peripheral blood of these same subjects. In three instances there was an increase 
in the percentage of Ia-positive T  ceils within 48 h  of skin testing, which was followed 
by a  fall. The decrease in Ia-positive T  cells coincided with the appearance of anti-Ia 
blocking activity in the sera of these subjects. In the remaining three subjects there 
was no initial rise in Ia-positive T  cells; there was, however, a  >50%  decrease in the K.  OKUDAIRA,  J.  S.  GOODWIN,  AND  R.  C.  WILLIAMS,  JR. 
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Fio.  2.  Anti-Ia blocking activity in sera and percent  la-positive T cells in blood of six individuals 
after  in  vivo  antigenic  challenge.  Six  normal  volunteers  were  given  either  intradermal  PPD 
(experiments  1-3),  Candida  antigens  (experiments  5  and  6),  or  subcutaneous  tetanus  vaccine 
(experiment  4).  In  all cases,  sera  obtained  between  2  and 4  d  after  immunization blocked  the 
binding of monoclonal anti-Ia antibody to  Ia-positive T  cells.  O, percent  la-positive T  cells;  0, 
percent  inhibition ofanti-Ia binding, 
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percentage  of these  cells occurring  later  in association  with the appearance  of anti-Ia 
blocking  activity.  In addition  to a  fall in the percentage  of Ia-positive  T  cells  in vivo, 
coincident  with  the  appearance  of the  anti-Ia  blocking  activity  in  the  sera,  we  also 
observed  a  decrease  in demonstrable  Ia antigen  on non-T  cells.  Fig.  3 shows a  dot plot 260  ANTI-IA ANTIBODY IN THE  SERA OF  NORMAL  SUBJECTS 
Fxc.  3.  FACS analysis of Ia-positive, E-rosette-negative  cells before and 4 d after skin testing with 
PPD in a  PPD-reactive  subject.  E-rosette-negative  cells were reacted  with fluorescein-conjugated 
monoclonal anti-Ia antibody and counted in the FACS. The vertical  axis represents  intensity of 
fluorescence, and the horizontal axis represents  degree of light  scatter,  which  correlates  with cell 
size. The percent of Ia-positive cells was 59% on day 0 and 44% on day 4. In addition, on day 4 
there was a marked diminution in fluorescence intensity in both small light-scatter  cells (mostly B 
cells) and  large  light-scatter  cells  (mostly  monocytes).  The cell samples  had  been stored  in  1% 
paraformaldehyde solution and were run at the same time without a change in the setting of the 
FACS. Cells from a  PPD-negative individual obtained before and 4 d after PPD administration 
showed no change either in percentage  of Ia-positive cells or intensity of fluorescence. 
from  the  FACS  of  E-rosette-negative  cells  obtained  before  and  4  d  after  PPD 
administration stained with directly fluorescein-conjugated monoclonal anti-Ia. 59% 
of the non-T cells were Ia positive on day 0  vs. 44% on day 4.  More impressive is the 
marked decrease in the fluorescence intensity after skin testing, suggesting that  there 
was a  decrease in density of surface Ia antigen on those cells that remained Ia positive. 
Similar data were obtained with another PPD-sensitive subject, whereas PPD admin- 
istration  to  a  PPD-negative  individual resulted  in  no  change  in  percentage  of Ia- 
positive non-T cells or in intensity of staining. 
We also measured anti-Ia blocking activity in sera by an ELISA method that  used 
an  Ia-positive  human  tumor  cell  adherent  to  microtiter  wells.  The  blocking  of 
monoclonal anti-Ia binding was assayed by preincubating the wells with test  human 
sera.  Fig. 4  presents such an analysis of anti-Ia blocking activity for the  test subject 
shown  in  experiment  1,  Fig.  2.  Results  of  the  two  methods  of measuring  anti-Ia 
blocking activity were virtually identical. 
We next examined which  component of the sera  from  subjects after  delayed-type 
hypersensitivity skin testing contained the anti-Ia blocking activity. In a  preliminary K.  OKUDAIRA, J.  S. GOODWIN, AND  R.  C.  WILLIAMS, JR.  261 
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FIG. 4.  Measurement ofanti-Ia blocking activity after PPD challenge using an ELISA technique. 
Sera obtained before and at days 1, 2, 3, 4, 5, 6, and 8 after intradermal PPD injections were tested 
for their ability to block the binding of monoclonal anti-Ia antibody (2 #g/ml) to B35 M cells that 
had been adhered to microtiter  wells. Binding of the monoclonal anti-la antibody was measured 
with affinity-purified, peroxidase-coupled goat anti-mouse IgG in an ELISA assay. There was a fall 
in optical density on days 3 to 5 after PPD administration, showing that the sera is blocking binding 
of the monoclonal anti-Ia. Calculating from the standard curve in Fig. 1, the optical density of 0.11 
on day 4 represents a 63% inhibition of anti-Ia binding. 
experiment using starch gel electrophoresis, we found that  the blocking activity was 
contained in the gamma globulin fraction (data not shown). We therefore isolated the 
IgG and  IgM  fractions of three sera by affinity chromatography  using rabbit anti- 
human  IgG or IgM conjugated to Sepharose 4B.  In each case, the blocking activity 
was contained entirely in the IgM fraction (Table I). 
The data above suggested that  blocking of monoclonal anti-Ia to Ia-positive ceils 
was mediated by an  IgM antibody. Table II provides evidence that  this blocking is 
not  genetically  restricted.  That  is,  sera  from  one  subject  blocked  the  binding  of 
monoclonal anti-Ia antibody to  Ia-positive T  cells from  subjects of several different 
DR haplotypes. These results suggested that the blocking activity could be caused by 
an IgM antibody directed against the common or core Ia determinants. To examine 
this directly, we absorbed sera with either an Ia-positive or Ia-negative human tumor 
cell line.  As  shown  in  Table  III,  absorption  with  B35  M  cells  (an  Ia-positive line) 
eliminated  the  blocking  activity  of sera  from  subjects  after  skin  testing,  whereas 
absorption with Molt 4 cells (Ia negative) had no effect. Similar results were obtained 
with three other Ia-positive cell lines (experiment 4 in Table III). 
The data presented above would appear to be strong though  indirect evidence for 
the presence of IgM anti-Ia antibodies after in vivo immunization. We attempted to 
demonstrate  this phenomenon ~  more  directly by using an  ELISA assay in which  Ia 
antigen purified from  B35  M  cells was adhered in microtiter wells, and the binding 
of IgG and IgM to these wells from the sera of subjects was measured before and after 
immunization. In addition, this method allowed us to roughly quantitate the amount 
of  anti-Ia  antibody  in  the  sera.  These  results  are  shown  in  Table  IV  for  three 
experiments on different donors. Before skin testing there was some baseline binding 262  ANTI-IA  ANTIBODY  IN  THE  SERA  OF  NORMAL  SUBJECTS 
TABLE  I 
Blocking of Anti-Ia Binding by Sera  from Subjects after Skin Testing: Effect of 
Whole Sera and of IgG and IgM Fractions Isolated by Affinity 
Chromatography 
Percent 
Experiment  Days after  Antigens  Immunoglobulin  anti-la inhi- 
skin test  class 
bition 
I  0  (-)  Whole serum  0% 
IgG  0% 
IgM  0% 
1  5th  PPD  Whole serum  49.9% 
IgG  0% 
IgM  35,5% 
4  3rd  Candida  Whole serum  33.0% 
t~  0% 
IgM  43.5% 
5  2nd  Candida  Whole serum  39.0% 
IgG  0% 
IgM  37.5% 
I00/~1  of whole or  100  ~1 of affinity-purified IgG  fractions of the sera were 
tested for their blocking activity. The IgG concentration was 3 mg/ml and the 
IgM was  I mg/ml. 
TABLE  II 
Blocking of Anti-la Binding by Sera  from Subjects after Skin Testing: Sera 
from One Subject Blocks the Binding of Anti-Ia Antibody to Ia-positive T 
Cells from Three Donors of Different Ia Types 
Percent Ia~positive T  cells 
Mean inhi-  Source of Sera  Source of T  cells 
bition 
A(DR 3,7)  B(DR 4,6)  C(DR  1,5) 
Normal sera (B)  19  10  19 
Normal sera (C)  21  10  18 
Sera  from  subject  A 
after skin testing: 
Day 0  22  12  23  0% 
Day 1  24  12  22  -2% 
Day 2  22  t 2  2,5  -4% 
Day 3  12  10  17  28% 
Day 4  14  7  13  40% 
Day 5  12  6  10  50% 
Day 6  28  9  16  8% 
Day 8  24  12  26  -7% 
Subject  A was given intradermal  PPD,  and the ability of his sera on days 0 
through 8 after PPD administration was tested for the ability to block binding 
of monoclonal anti-Ia to Ia-positive T  cells that were autologous (subject A) or 
that  were  two other donors of different  DR  haplotypes  (subjects B  and C). 
Sera on days 3, 4, and 5 blocked the binding of monoclonal antibody to the 
three different target cells to a similar extent. The mean percent inhibition of 
monoclonal anti-Ia binding to the Ia-positive T  cells from the three donors by 
the sera is given in the last column. K.  OKUDAIRA, J.  S.  OOODWIN,  AND  R.  C.  WILLIAMS, JR. 
TABLE  III 
Anti-Ia Blocking Activity in Sera of Subjects after Skin Testing: Effect of 
Absorption with Ia-positive and Ia-negative Cell Lines 
Experiment  Days after skin  Absorbed with  Percent anti-Ia 
test  inhibition 
l  4th  --  40.0% 
Molt-4  39.0% 
B-35 M  8.O% 
2  2nd  --  51.0% 
Molt-4  37.0% 
B-35 M  4.0% 
3  2nd  --  42.0% 
Molt-4  39.0% 
B-35 M  16.0% 
4  3rd  --  24.0% 
Molt-4  29.0% 
B-35 M  0% 
Moh-3  9% 
WI-L2  5% 
RPMI 4098  5% 
Sera from four subjects were tested for their ability to block monoelonal anti- 
Ia binding to Ia-positive T  cells before and after absorption with Ia-negative 
(Molt-4)  and Ia-positive (B-35  M, Molt 3, WI-L2, RPMI 4098)  human cell 
lines. Percent inhibition by sera was calculated as compared with the amount 
of Ia-positive cells incubated in normal serum. 
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TABLE  IV 
Measurement of Anti-Ia Antibodies in Sera of Subjects before and after Delayed 
Hypersensitivity Skin Testing Using an ELISA Assay with Purified Ia 
Antigen 
Time after skin  Anti-Ia antibody 
Inhibition  Percent anti-Ia 
test  IgM  IgG 
I.Lg/ml 
Experiment 1  Day 0  1.2  0.7  0% 
(PPD)  Day 2  3.3  0.65  43% 
Experiment 2  Day 0  0.8  0.9  7% 
(Clandida)  Day 4  2.5  1.0  57% 
Experiment 3  Day 0  1.8  1.1  0% 
(PPD)  Day 2  3.8  1.2  43% 
Sera from  three subjects taken  before and after skin testing were tested for 
anti-Ia antibodies in an ELISA assay in which purified Ia antigen was adhered 
to microtiter plates. The sera after skin testing that gave the greatest amount 
of inhibition of monoclonal anti-la antibody to la-positive targets (right-hand 
column) were selected for testing. The amount of IgG and IgM bound to the 
wells was estimated by comparison to a standard curve. The experiments listed 
here are not the same as in Fig. 2. 
of both  IgG  and  IgM  to  the  Ia-coated  plates.  After  skin  testing,  the  amount  of IgM 
bound  to  the  plates  increased  coincident  with  the  appearance  of anti-Ia  blocking 
activity  in  the sera, whereas  the  amount  of IgG  anti-Ia  was unchanged, 264  ANTI-IA ANTIBODY IN THE SERA OF  NORMAL SUBJECTS 
Discussion 
We  demonstrated  that  anti-Ia-reactive  antibodies  occur  after  in  vivo  antigenic 
stimulation in normal individuals. These antibodies were noted shortly after antigenic 
challenge, with the peak response occurring 2-5 d after immunization and disappear- 
ing  by  the  7th  d.  Anti-Ia  antibodies  occurring  in  normal  subjects  after  in  vivo 
antigenic stimulation were not  HLA-DR restricted and reacted with Ia antigens on 
autologous and allogeneic T  cells. Recently, Yu et al. reported that Ia-positive T  cells 
increase after in vivo immunization  (17).  We also found an increase in Ia-positive T 
cells in three of the six subjects studied.  A more constant  finding was the occurrence 
of anti-Ia antibody, the peak of which coincided in all cases with a drop in Ia-positive 
T  cells. 
The physiologic functions of naturally occurring anti-Ia antibodies that are present 
in serum after antigenic stimulation  in normal subjects are not presently known.  In 
the autologous mixed lymphocyte response, it has been reported that T cells proliferate 
in response to autologous non-T cells (26, 27); an inhibitory effect of anti-Ia antibodies 
on  this  response has  been  reported  from several  laboratories  (28-30).  We  recently 
reported (22) 2 that the sera of patients with active SLE contain anti-Ia antibodies of 
the IgG and IgM class. These anti-Ia antibodies blocked the binding of monoclonal 
anti-Ia antibodies to Ia-positive resting T  cells, to activated T  cells, and to non-T cell 
lymphocyte populations  (22).  Among the SLE patients studied, there was an inverse 
correlation between the amount of circulating anti-Ia antibodies and the percentage 
of  Ia-positive  T  cells,  suggesting  a  role  for  anti-Ia  antibodies  in  the  control  of 
expression of Ia antigen on T  cells. In addition,  IgG anti-Ia antibodies in SLE sera, 
but not IgM anti-Ia antibodies, blocked the autologous MLR. 2 In preliminary studies, 
we  could  not  find  any  effect  on  the  autologous  MLR  of sera  containing  anti-Ia 
antibodies occurring after in vivo immunization  in normals. This might be because 
the anti-Ia antibody in  these subjects was IgM, a  class of anti-Ia that  in sera from 
SLE  patients  also  did  not  affect  the  autologous  MLR.  Alternatively,  it  might  be 
because of the small amount of anti-Ia antibody that we are measuring. Concentra- 
tions of monoclonal anti-Ia antibodies similar to the concentrations of the naturally 
occurring IgM anti-Ia antibody (1:5  dilution  of 2 ~g/ml; see Table IV) also do not 
inhibit  the  autologous  MLR;  higher  concentrations  are  required  (K.  Okudaira, J. 
Goodwin,  and  R.  C.  Williams,  unpublished  data).  It is also possible that  naturally 
occurring  anti-Ia antibodies  might  possess different  functional  effects according  to 
their precise antigenic specificity. Supporting this point, Engleman et al. (30) reported 
different effects of different  monoclonal anti-Ia antibodies on the autologous mixed 
lymphocyte response. 
It is certainly unexpected that an antigen as widely expressed in vivo as is Ia could 
elicit an antibody response. It is also unclear why free anti-Ia antibody should exist in 
the sera in the presence of Ia(+) cells. It would appear that much of the anti-Ia did 
bind  to Ia (St) T  cells and  non-T cells,  resulting in a  decrease in Ia(+) T  cells and 
non-T cells and also in a decrease in the density of surface Ia on the non-T cells (Figs. 
2 and 3).  Other examples of free antibody circulating in the presence of endogenous 
20kudaira,  K., R. Searles, J. Goodwin, and R. C. Williams,  Jr.  1982. Antibodies against Ia antigen in 
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antigen include antilymphocyte antibodies in some autoimmune diseases and also the 
presence of antibodies against erythrocyte antigens in autoimmune hemolytic anemia. 
Because antigen-reactive T  cells recognize antigenic  determinants  in conjunction 
with self Ia antigens (31-33), anti-Ia antibodies occurring after in vivo immunization 
could conceivably influence antigen presentation  by Ia-positive accessory cells.  It is 
also possible that  these naturally occurring anti-Ia antibodies could provide signals 
for specific antibody formation systems. In this regard, the anti-Ia antibody detected 
in the serum might represent a  "leaking" of this antibody from the skin test site, and 
whatever function this anti-Ia antibody has might be restricted to the local site of the 
immune reaction. Although the naturally occurring anti-Ia antibodies described here 
after in vivo antigenic stimulation are not restricted to autologous HLA-DR pheno- 
types, these anti-Ia antibodies occur with specific antigen stimulation. This phenom- 
enon is reminiscent of the idiotype-anti-idiotype network concept. 
Summary 
We showed that sera from normal subjects after antigenic challenge with intrader- 
mal PPD or Candida antigens or with subcutaneous tetanus vaccine contain a factor 
that blocks the binding of mouse monoclonal anti-Ia antibody to Ia-positive T  cells 
or to B35 M  cells, an Ia-positive human B cell line. The blocking activity appears 48 
to 72 h  after antigenic challenge and is gone by day 7. The appearance of the anti-Ia 
blocking activity coincided with a  drop in the percentage of Ia-positive T  cells and 
non-T cells in the peripheral blood of these subjects and also with a  decrease in the 
density of surface Ia on the non-T cell population. The blocking was not genetically 
restricted;  that is, serum from a  given subject blocked anti-Ia binding to Ia-positive 
T  cells of subjects with different DR haplotypes. The blocking activity was contained 
in the IgM fraction of the sera. The blocking activity of the sera was eliminated after 
absorption of the sera with  Ia-positive but not with Ia-negative human cell lines.  It 
would appear, therefore, that the blocking of monoclonal anti-Ia binding is caused by 
an IgM anti-Ia antibody that appears in normals after in vivo antigenic challenge. 
Received  for publication 30 November 1981. 
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